Bicêtre Hospital

Running trials

• Not yet recruiting

  Safety and Efficacy of a STOPping Strategy Versus Classical Maintenance Dose of JAK Inhibitors in Deep Remission Patients With Ulcerative Colitis

  NCT07718529· Phase 4· Assistance Publique Hopitaux De Marseille· Source

• Not yet recruiting

  FirST Lines of Biologics in pAtients With ulceRaTivE Colitis: a Randomised Controlled Trial

  NCT07576452· Phase 4· University Hospital, Clermont-Ferrand· Source

• Not yet recruiting

  A Phase 2 trial of AGMB-447 in participants with idiopathic pulmonary fibrosis

  2026-526404-71-00· Phase 2· Agomab Spain S.L.U.· Source

• Not yet recruiting

  AAV9-ASAH1 intracisterna magna Gene Therapy (GNT0009) in Patients with Spinal Muscular Atrophy with Progressive Myoclonic Epilepsy (SMA - PME)

  2026-527323-10-00· Phase 1/2· Genethon· Source

• Not yet recruiting

  Clinical, Electrophysiological and Genetic Characteristics of Hereditary and Inflammatory Polyneuropathies in France

  NCT07851844· Assistance Publique - Hôpitaux de Paris· Source

• Not yet recruiting

  To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)

  NCT07116473· Phase 3· Eidos Therapeutics, a BridgeBio company· Source

• Not yet recruiting

  Discontinuation Versus Continuation of Riociguat Monotherapy in Chronic Thromboembolic Pulmonary Hypertension Successfully Treated With Balloon Pulmonary Angioplasty

  NCT07644377· Phase 3· Assistance Publique - Hôpitaux de Paris· Source

• Not yet recruiting

  A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)

  NCT07503340· Phase 2· Hoffmann-La Roche· Source

• Recruiting

  A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia

  NCT07623200· Phase 3· Incyte Corporation· Source

• Not yet recruiting

  Epidemiology of Invasive Bacterial Infections in Children With Sickle Cell Disease in France Between 2020 and 2025

  NCT07639008· Assistance Publique - Hôpitaux de Paris· Source

• Recruiting

  Optimal Care With Guselkumab in Crohn's Disease / OPTIM Study A Prospective Open Label Interventional, Multicenter Study

  NCT07616687· Phase 4· Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives· Source

• Recruiting

  A Study of TAK-755 in Adults With Acute Ischemic Stroke

  NCT07392450· Phase 2· Takeda· Source

• Recruiting

  A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A

  NCT07416526· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A

  NCT07416604· Phase 3· Hoffmann-La Roche· Source

• Not yet recruiting

  Factors Associated With Blood Pressure Control Failure to Intravenous Labetalol in Severe Preeclampsia

  NCT07547046· Assistance Publique - Hôpitaux de Paris· Source

• Not yet recruiting

  Biological Collection for the Purpose of Exploring Genetic and Clinical-biological Factors Associated With Variability in Response to Mavacamten in the Treatment of Obstructive Hypertrophic Cardiomyopathy

  NCT07439952· Assistance Publique - Hôpitaux de Paris· Source

• Recruiting

  TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy

  NCT07223203· Phase 3· Alnylam Pharmaceuticals· Source

• Recruiting

  A phase Ib, open-label, ascending dose study to assess safety, tolerability and pharmacokinetics of PIT565 in participants with rheumatoid arthritis (RA)

  2024-520196-27-00· Phase 1· Novartis Pharma AG· Source

• Not yet recruiting

  Interest of Preoperative Arteriography to Identify the Adamkiewicz Artery Before Surgery for Basi-thoracic Neuroblastic Tumors

  NCT06798532· Assistance Publique - Hôpitaux de Paris· Source

• Not yet recruiting

  CMV-associated Immunomodulation in Renal Transplant Patients

  NCT06976008· Assistance Publique - Hôpitaux de Paris· Source

• Recruiting

  Interest of Early Erectile Rehabilitation With Sildenafil After Radiotherapy and Proctectomy for Rectal Cancer

  NCT06123156· Phase 3· University Hospital, Rouen· Source

• Not yet recruiting

  Impact of Comprehensive Geriatric Management on Morbidity and Quality of Life in Elderly Patients Undergoing Major Hepatectomy and Pancreaticoduodenectomy for Cancer

  NCT06999512· Phase 2/3· Assistance Publique - Hôpitaux de Paris· Source

• Recruiting

  A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP

  NCT06920004· Phase 3· argenx· Source

• Recruiting

  Intra-Arterial Thrombolysis After SUCCESSful Reperfusion in Anterior Circulation Ischemic Stroke

  NCT06768138· Phase 3· Central Hospital, Nancy, France· Source

• Recruiting

  Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

  NCT06563895· Phase 3· Eidos Therapeutics, a BridgeBio company· Source

• Recruiting

  Target Engagement of EXL01 in the Prevention of Post-operative Recurrence of Crohn's Disease

  NCT06925061· Phase 2· Madeleine Bezault· Source

• Recruiting

  An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

  NCT06668181· Phase 3· UCB Biopharma SRL· Source

• Recruiting

  PMCF Registry to Describe the Safety and Performance of p64, p48 MW and p64 MW in France

  NCT07748572· Phenox GmbH· Source

• Recruiting

  A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)

  NCT06747949· Phase 3· Amgen· Source

• Recruiting

  Pharmacokinetics, Efficacy and Safety of Twice Daily Dosing Regimen of Hydroxycarbamide Dispersible Tablets in Children With Sickle Cell Disease

  NCT06578507· Phase 2· Theravia· Source

• Recruiting

  Early efficacy of ketamine compared to placebo, in add-on therapy of venlafaxine for inpatients with severe unipolar major depressive episodes: a double blind randomized controlled trial

  2023-506597-12-00· Phase 3· Assistance Publique Hopitaux De Paris· Source

• Recruiting

  Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)

  NCT06274801· Phase 3· Gossamer Bio USA, Inc.· Source

• Recruiting

  A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab

  NCT06100744· Phase 3· AbbVie· Source

• Recruiting

  Phase II Trial of ART + Dual bNAbs vs. ART + Placebo During Primary HIV-1 Infection-impact on Post-ART Control

  NCT05300035· Phase 2· ANRS, Emerging Infectious Diseases· Source

• Recruiting

  An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants

  NCT05835310· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Circulating Activin-A and FSTL3 in Precapillary Pulmonary Hypertension

  NCT07253363· Assistance Publique - Hôpitaux de Paris· Source

• Active, not recruiting

  Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib in Adult Participants With Moderate to Severe Crohn's Disease (CD) in Real World Clinical Practice.

  NCT05930275· AbbVie· Source

• Recruiting

  Low Stable Pressure Pneumoperitoneum in Colorectal Surgery (CROSS STUDY)

  NCT06154785· Bordeaux Colorectal Institute Academy· Source

• Active, not recruiting

  Permanent Intracranial Stenting for Acute Ischemic Stroke Related to a Refractory Large Vessel Occlusion

  NCT06071091· Assistance Publique - Hôpitaux de Paris· Source

• Active, not recruiting

  A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.

  NCT05985915· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome

  NCT05946941· Phase 3· Bristol-Myers Squibb· Source

• Active, not recruiting

  An Observational Study to Assess Change in Disease Activity and Adverse Events In Adult Participants With Moderate to Severe Active Crohn's Disease (CD)

  NCT05841537· AbbVie· Source

• Recruiting

  Efficacy of a Sequential Treatment Strategy in Rheumatoid Arthritis

  NCT05428488· Phase 3· University Hospital, Montpellier· Source

• Recruiting

  Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0

  NCT05476939· Phase 3· Gustave Roussy, Cancer Campus, Grand Paris· Source

• Active, not recruiting

  An Observational Study to Assess Change in Disease Activity and Adverse Events of Upadacitinib in Adult Participants With Moderate to Severe Ulcerative Colitis (UC) in Real-World Practice

  NCT05494606· AbbVie· Source

• Recruiting

  Hizentra® in Inflammatory Neuropathies - pHeNIx Study

  NCT04672733· CSL Behring· Source

• Active, not recruiting

  A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)

  NCT05123703· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  Diagnostic Performance of Spot Urine Sample for the Monoclonal Components Detection in Patients With Multiple Myeloma

  NCT05208086· Intergroupe Francophone du Myelome· Source

• Recruiting

  Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA

  NCT05181735· Phase 1/2· Groupe Francophone des Myelodysplasies· Source

• Active, not recruiting

  Evaluation of Salivary RNAs in the Presence of an Adnexal Mass of Ovarian Origin

  NCT05514028· ZIWIG· Source

Showing 50 of 76.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Colorectal cancer4 recruiting
• Stroke4 recruiting
• Childhood cancers3 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)3 recruiting
• Rheumatoid arthritis3 recruiting
• Sickle cell disease3 recruiting
• Amyloidosis2 recruiting
• Crohn's disease2 recruiting
• Haemophilia2 recruiting
• High blood pressure2 recruiting
• Psoriatic arthritis2 recruiting
• Ulcerative colitis2 recruiting
• Ankylosing spondylitis1 recruiting
• Brain aneurysm1 recruiting
• Charcot-Marie-Tooth disease1 recruiting
• Chronic myeloid leukaemia1 recruiting
• Coeliac disease1 recruiting
• Cytomegalovirus infection1 recruiting
• Depression1 recruiting
• Epilepsy1 recruiting
• Hearing loss1 recruiting
• HIV1 recruiting
• Hypertrophic cardiomyopathy1 recruiting
• Idiopathic pulmonary fibrosis1 recruiting
• Liver and biliary tract cancer1 recruiting
• Lung cancer1 recruiting
• Lupus (SLE)1 recruiting
• Multiple sclerosis1 recruiting
• Myelodysplastic syndromes1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Neuroblastoma1 recruiting
• Pancreatic cancer1 recruiting
• Psoriasis1 recruiting
• Pulmonary arterial hypertension1 recruiting
• Sjögren's disease1 recruiting
• Spinal muscular atrophy1 recruiting

Closed trials

• Completed

  A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease

  NCT06926660· Phase 2· Boehringer Ingelheim· Source

• Completed

  Perinatal Thoraco-abdomino-pelvic Tumors Study

  NCT06365268· Assistance Publique - Hôpitaux de Paris· Source

• Completed

  Safety and Efficacy of NMD670 in Adult Patients with Type 1 and Type 2 Charcot-Marie-Tooth Disease

  2023-507892-23-00· Phase 2· NMD Pharma A/S· Source

• Completed

  A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary Arterial Hypertension (PAH) (TROPOS).

  NCT05975905· Phase 2· Keros Therapeutics Inc.· Source

• Completed

  A proof of concept and dose-finding study of XXB750 in patients with heart failure

  2023-504678-39-00· Phase 2· Novartis Pharma AG· Source

• Recruiting

  Treatment Resistant Depression and Vagus Nerve Stimulation

  NCT05952674· Assistance Publique - Hôpitaux de Paris· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity

  NCT06104124· Phase 3· Amgen· Source

• Completed

  Evaluation by a Vineland II Scale of Long-term Development of Children With Pyridoxine Dependent Epilepsy

  NCT06054347· University Hospital, Angers· Source

• Completed

  Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)

  NCT05934526· Phase 3· GB002, Inc.· Source

• Completed

  An 18-month study to assess joint outcomes in patients with haemophilia A or B on prophylaxis with efmoroctocog alfa or eftrenonacog alfa

  2022-502921-16-00· Phase 4· Swedish Orphan Biovitrum AB (publ)· Source

• Recruiting

  Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active SLE (POETYK SLE-1)

  2022-500699-76-00· Phase 3· Bristol-Myers Squibb Services Unlimited Company· Source

• Completed

  REVErsing Airway Remodelling With Tezepelumab

  NCT05651841· Phase 3· University Hospital, Montpellier· Source

• Terminated

  Hemophilia Non-Interventional Study Prior to SerpinPC Intervention (PRESent-5)

  NCT05605678· ApcinteX Ltd· Source

• Completed

  A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis

  NCT05083182· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

  NCT05349214· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT) or A Phase 2b/3, Randomized, Controlled, 24-week Dose Ranging and Confirmatory Study of AV-101 in Patients with PAH

  NCT05036135· Phase 2/3· Aerovate Therapeutics Inc.· Source

• Suspended

  Anakinra vs Prednisone to Treat Gout Flare in Patients With Chronic Kidney Disease Stage 4/5 or Renal Transplantation

  NCT04844814· Phase 2· Assistance Publique - Hôpitaux de Paris· Source

• Completed

  Adherence of Diuretics in Pulmonary Hypertension

  NCT05167968· Assistance Publique - Hôpitaux de Paris· Source

• Completed

  Multicenter Validation of the Salivary miRNA Signature of Endometriosis

  NCT05244668· ZIWIG· Source

• Completed

  Comparison of Corticosteroids vs Placebo on Duration of Ventilatory Support During Severe Acute Exacerbations of COPD Patients in the ICU

  NCT04163536· Phase 3· Versailles Hospital· Source

• Completed

  Effect of Increased Oxytocin Doses on the Mode of Delivery in Obese Primiparous Women With Spontaneous or Induced Labour

  NCT04760496· Phase 4· Assistance Publique - Hôpitaux de Paris· Source

• Completed

  Coating to Optimize Aneurysm Treatment In The New Flow Diverter Generation

  NCT04870047· Phenox GmbH· Source

• Completed

  Initial Dual Oral Combination Therapy Versus Standard-of-care Initial Oral Monotherapy Prior to Balloon Pulmonary Angioplasty in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension

  NCT04780932· Phase 2/3· Assistance Publique - Hôpitaux de Paris· Source

• Recruiting

  Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome

  NCT03708900· Phase 2· RECORDATI GROUP· Source

• Completed

  Medication Reconciliation in Pulmonary Hypertension

  NCT04744584· Assistance Publique - Hôpitaux de Paris· Source

• Terminated

  Interest of the Smartphone Application "MonCœur" in the Follow-up of Patients With Heart Failure

  NCT04198779· French Cardiology Society· Source

• Completed

  Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy

  NCT03993912· Phase 3· University Hospital, Lille· Source

• Completed

  Prospective, randomised, placebo-controlled study of polyvalent intravenous immunoglobulins for the treatment of primary Sjögren's syndrome associated painful sensory neuropathies

  NCT03700138· Phase 3· Les Hopitaux Universitaires De Strasbourg· Source

• Completed

  Non-Interventional Registry Study to Evaluate the Effectiveness of TheraSphere® in the Treatment of Hepatocellular Carcinoma (HCC)

  NCT04069468· Boston Scientific Corporation· Source

• Completed

  A Trial of the May Health Device in Transvaginal Ablation of Ovarian Tissue Under ULTRAsound Visualization in Women With PCOS Infertility

  NCT03760926· May Health· Source

• Terminated

  Efficacy and Safety of Thrombectomy in Stroke With Extended Lesion and Extended Time Window

  NCT03094715· University Hospital Heidelberg· Source

• Completed

  FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation

  NCT03584711· Phase 2· Federation Francophone de Cancerologie Digestive· Source

• Completed

  Study Venetoclax Effectiveness and Real-Life Treatment Management in Participants With Chronic Lymphocytic Leukemia

  NCT03415035· AbbVie· Source

• Completed

  A Study of BAX 888 in Male Adults With Severe Hemophilia A

  NCT03370172· Phase 1/2· Baxalta now part of Shire· Source

• Recruiting

  Second STOP After Pioglitazone Priming in CML Patients

  NCT02889003· Phase 2· Versailles Hospital· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Pulmonary arterial hypertension83 works · 10 trials
• Crohn's disease25 works · 5 trials
• Haemophilia13 works · 5 trials
• Amyloidosis12 works · 3 trials
• Brain aneurysm9 works · 3 trials
• Sjögren's disease7 works · 6 trials
• Cushing's syndrome5 works · 1 trial